NCT00720382

Brief Summary

The purpose of this study is to determine if one allergy treatment (0.15% azelastine hydrochloride) is as safe as mometasone furoate (nasonex) alone.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
703

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Mar 2007

Shorter than P25 for phase_3

Geographic Reach
1 country

59 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2007

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2008

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2008

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

July 21, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 22, 2008

Completed
1.5 years until next milestone

Results Posted

Study results publicly available

January 15, 2010

Completed
Last Updated

May 21, 2015

Status Verified

May 1, 2015

Enrollment Period

1.3 years

First QC Date

July 21, 2008

Results QC Date

November 6, 2009

Last Update Submit

May 4, 2015

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change From Baseline on Direct Visual Nasal Exams to 12 Months

    Examination of head and neck (scale: None, Mild, Moderate, Severe) for Epistaxis, Mucosal Edema, Nasal Discharge, Mucosal erythema, Mucosal Bleeding, and Crusting of mucosa. Nasal irritation was rated: 0 = None, Grade 1A = focal irritation, Grade 1B = superficial mucosal erosion, Grade 2 = moderate mucosal erosion, Grade 3 = ulceration, Grade 4 = septal perforation

    Change from baseline to 12 months

Other Outcomes (1)

  • Change From Baseline to 12 Months in the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Compared to Placebo in Subjects 18 Years of Age and Older

    change from baseline to 12 months

Study Arms (2)

1

EXPERIMENTAL

0.15% azelastine hydrochloride 1644 mcg

Drug: 0.15% azelastine hydrochloride

2

EXPERIMENTAL

Mometasone furoate 200 mcg

Drug: Mometasone furoate

Interventions

1644 mcg (205.5 mcg/spray) 2 sprays per nostril twice a day/AM and PM

1

200 mcg (50 mcg/spray) 2 sprays per nostril Once a day (AM)

2

Eligibility Criteria

Age12 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Male and female patients 12 years and older with a compatible history greater than or equal to 1 year of rhinitis due to perennial allergies.
  • Must be willing and able to provide informed consent and to participate in all study procedures
  • Must be in generally good health
  • Positive skin test to a prevalent perennial allergen

You may not qualify if:

  • On nasal examination, the presence of nasal mucosal erosion, nasal ulceration or nasal septal perforation
  • Use of any investigational drug within 30 days of the first visit
  • Any nasal surgery or sinus surgery within the previous year
  • Presence of any hypersensitivity to drugs similar to azelastine or mometasone furoate and to either sorbital or sucralose
  • Women who are pregnant or nursing
  • Women who are not using an acceptable method of birth control
  • Nasal Diseases likely to affect deposition of intranasal medication, such as sinusitis, rhinitis medicamentosa or clinically significant nasal polyposis or nasal structural abnormalities.
  • Asthma or other lung diseases such as COPD. Mild asthma symptoms may be considered after consultation with investigator.
  • Patients with Arrythmia
  • Patients with know history of alcohol and drug abuse
  • Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor, might significantly alter the evaluation of the study.
  • Use of medications that could affect the study results

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (59)

Center of Research Excellence, LLC

Oxford, Alabama, 36203, United States

Location

AABI Associates Medical Group

Fountain Valley, California, 92708, United States

Location

Allergy and Asthma Specialist Medical Group

Huntington Beach, California, 92647, United States

Location

West Coast Clinical Trials

Long Beach, California, 90806, United States

Location

Allergy Research Foundation

Los Angeles, California, 90025, United States

Location

Southern California Research

Mission Viejo, California, 92691, United States

Location

Allergy Associates Medical Group Inc

San Diego, California, 92120, United States

Location

Allergy and Asthma Medical Group and Research Center

San Diego, California, 92123, United States

Location

Allergy & Asthma Associates of Santa Clara Valley Research Cntr

San Jose, California, 95117, United States

Location

Bensch Research Associates

Stockton, California, 95207, United States

Location

Allergy and Asthma Clinical Research, Inc.

Walnut Creek, California, 94598, United States

Location

Asthma and Allergy Associates

Colorado Springs, Colorado, 80907, United States

Location

Allergy and Asthma Care of Florida

Ocala, Florida, 34471, United States

Location

Allergy and Asthma DTC

Tallahassee, Florida, 32308, United States

Location

Georgia Pollens Clinical Research Centers Inc

Albany, Georgia, 31707, United States

Location

Aeroallergy Research Laboratories of Savannah

Savannah, Georgia, 31406, United States

Location

Clinical Research Atlanta

Stockbridge, Georgia, 30281, United States

Location

Sneeze, Wheeze and Itch Associates

Normal, Illinois, 61761, United States

Location

Kansas City Allergy and Asthma

Overland Park, Kansas, 66210, United States

Location

RX R+D

Metairie, Louisiana, 70001, United States

Location

Institute for Asthma and Allergy PC

Wheaton, Maryland, 20902, United States

Location

Northeast Medical Research Associates

North Dartmouth, Massachusetts, 02747, United States

Location

Clinical Research Institute

Minneapolis, Minnesota, 55402, United States

Location

Clinical Research Institute

Plymouth, Minnesota, 55441, United States

Location

The Clinical Research Center

St Louis, Missouri, 63141, United States

Location

The Asthma and Allergy Center

Papillion, Nebraska, 68046, United States

Location

Las Vegas Physicians Research Group

Henderson, Nevada, 89052, United States

Location

Allergy and Asthma Research NJ inc

Mount Laurel, New Jersey, 08054, United States

Location

Atlantic Research Center

Ocean City, New Jersey, 07712, United States

Location

Dr. Perin

Teaneck, New Jersey, 07666, United States

Location

Medical Research Associates of CNY, PLLC

North Syracuse, New York, 13212, United States

Location

AAIR Research Center

Rochester, New York, 14618, United States

Location

North Carolina Clinical Research

Raleigh, North Carolina, 27607, United States

Location

Wake Research Associates, LLC

Raleigh, North Carolina, 27612, United States

Location

Bernstein Clinical Research Center

Cincinnati, Ohio, 45231, United States

Location

New Horizon's Clinical Research

Cincinnati, Ohio, 45252, United States

Location

Oklahoma Institute of Allergy and Asthma Clinical

Edmond, Oklahoma, 73003, United States

Location

Allergy, Asthma and Clinical Research Center

Oklahoma City, Oklahoma, 73120, United States

Location

Allergy Asthma and Dermatology Research

Lake Oswego, Oregon, 97035, United States

Location

Clinical Research Institute of Southern Oregon, PC

Medford, Oregon, 97504, United States

Location

Allergy and Asthma Specialist PC

Blue Bell, Pennsylvania, 19422, United States

Location

Allergy and Consultants of NJ/PA

Collegeville, Pennsylvania, 19426, United States

Location

Allergy and Clinical Immunology Associates

Pittsburgh, Pennsylvania, 15241, United States

Location

Asthma and Allergy Research Associate

Upland, Pennsylvania, 19013, United States

Location

Asthma, Nasal Disease & Allergy Research Center of New England

Providence, Rhode Island, 02906, United States

Location

National Allergy, Asthma and Urticaria of Charleston

Charleston, South Carolina, 29407, United States

Location

Allergy and Asthma Associates

Austin, Texas, 78731, United States

Location

AARA Research Center

Dallas, Texas, 75231, United States

Location

Pharmaceutical Research & Consulting Inc

Dallas, Texas, 75231, United States

Location

Western Sky Medical Research

El Paso, Texas, 79902, United States

Location

SWAAA Research Center

Houston, Texas, 77074, United States

Location

Central Texas Health Research

New Braunfels, Texas, 78130, United States

Location

Biogenics Research Institute

San Antonio, Texas, 78229, United States

Location

Sylvana Research Associates

San Antonio, Texas, 78229, United States

Location

Live Oak Allergy and Asthma Clinic

San Antonio, Texas, 78233, United States

Location

Allergy Asthma Research Institute

Waco, Texas, 76712, United States

Location

VA Adult and Pediatric Allergy and Asthma

Richmond, Virginia, 23229, United States

Location

Asthma, Inc.

Seattle, Washington, 98105, United States

Location

Advanced Healthcare

Milwaukee, Wisconsin, 53209, United States

Location

Related Publications (1)

  • Bousquet J, Klimek L, Kuhl HC, Nguyen DT, Kumar Ramalingam R, Canonica GW, Berger WE. In perennial allergic rhinitis, RQLQ is improved similarly by Azelastine 0.15 and mometasone furoate. World Allergy Organ J. 2025 Jan 8;18(1):101021. doi: 10.1016/j.waojou.2024.101021. eCollection 2025 Jan.

MeSH Terms

Conditions

Rhinitis, Allergic, Perennial

Interventions

azelastineMometasone Furoate

Condition Hierarchy (Ancestors)

Rhinitis, AllergicRhinitisNose DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityOtorhinolaryngologic DiseasesHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Intervention Hierarchy (Ancestors)

PregnadienediolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic Compounds

Results Point of Contact

Title
William Wheeler, PhD
Organization
Meda Pharmaceuticals

Study Officials

  • Lewis M. Fredane, MD

    Meda Pharmaceuticals

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 21, 2008

First Posted

July 22, 2008

Study Start

March 1, 2007

Primary Completion

June 1, 2008

Study Completion

July 1, 2008

Last Updated

May 21, 2015

Results First Posted

January 15, 2010

Record last verified: 2015-05

Locations